Skip to Content

ALPS Medical Breakthroughs ETF SBIO ETF Analysis

| Medalist Rating as of | See ALPS Investment Hub

Morningstar’s Analysis SBIO

Will SBIO outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Weakness in ALPS Medical Breakthroughs ETF's Process and People Pillar ratings limits this strategy to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the lowest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor